Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 221.4 SEK 4.04% Market Closed
Market Cap: 30B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Total Equity
kr13.1B
CAGR 3-Years
32%
CAGR 5-Years
50%
CAGR 10-Years
42%
Biogaia AB
STO:BIOG B
Total Equity
kr2B
CAGR 3-Years
5%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Total Equity
kr661.8m
CAGR 3-Years
32%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Total Equity
kr1.4B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
27%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Total Equity
kr37.1B
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
23%
BioArctic AB
STO:BIOA B
Total Equity
kr1B
CAGR 3-Years
5%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
30B SEK
Industry
Biotechnology

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

VITR Intrinsic Value
139.61 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Total Equity?
Total Equity
13.1B SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Total Equity amounts to 13.1B SEK.

What is Vitrolife AB's Total Equity growth rate?
Total Equity CAGR 10Y
42%

Over the last year, the Total Equity growth was -25%. The average annual Total Equity growth rates for Vitrolife AB have been 32% over the past three years , 50% over the past five years , and 42% over the past ten years .

Back to Top